British builders grow more pessimistic: PMI rises to an eight-month high, but major projects are still being collectively shelved
UK builders became more pessimistic in September. The PMI rose to an eight-month high of 46.1 but remains in contraction territory; weak orders and Middle East conflicts are causing companies to delay project decisions.
Zhihu Finance APP has noted that a key survey shows British builders became less optimistic about the outlook in September, with many postponing major project decisions, even though there are signs the industry's downturn is easing.
The S&P Global Purchasing Managers' Index (PMI) rose to an eight-month high of 46.1, up from 44.3 in August. This result is better than economists' expectations of 44.9, but the sector still remains below the 50 threshold that separates output growth from contraction.
Although the residential construction sub-index improved, it remains deeply in contraction territory, continuing a prolonged slump that has dashed the Labour Government's hopes of leading a housing boom.
The downturn in the UK construction industry continued in September
Rising interest rates, inflation, and weak orders have dampened the sector's growth prospects, with companies postponing decisions due to uncertainty caused by Middle East conflicts. The future activity index fell to its lowest since May.
Tim Moore, Director of Economics at S&P Global Market Intelligence, said, "Total new orders were relatively weak in September, and construction firms reported longer sales conversion cycles with clients delaying major project decisions." "This was attributed to weak demand and geopolitical tensions, with some businesses also noting severe input cost increases putting them under pressure."
When the war between the US and Iran broke out and inflationary pressures surged once again, the construction industry was already in a prolonged slump. It has consistently been the weakest link among the UK’s private sectors covered by the PMI survey, while the services and manufacturing sectors have so far weathered the shock of the conflict.
Just before the outbreak of war, builders saw their costs rise at the slowest pace in seven months. However, Moore warned that the trend of easing price pressures "seems unlikely to persist given the recent rise in fuel prices and transportation costs."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uber (UBER.US) plans to acquire ezCater for $2.3 billions in cash to expand corporate catering services
Uber (UBER.US) will acquire food service company ezCater Inc. for $2.3 billion in cash, a move that will help the Uber Eats delivery platform reach more corporate clients.
BUZZ - RPM shares drop as downgraded outlook overshadows Q1 earnings beat
October 6 – ** Paint manufacturer RPM International (RPM.N) shares fell 2% to close at $93.50 after releasing its first-quarter earnings report ** The company expects mid-single-digit growth in adjusted EBITDA for fiscal year 2027, compared to its previous forecast of 5% to 10% ** The company expects consolidated sales to achieve mid-single-digit growth, roughly in line with the previous estimate of 3% to 7% ** According to LSEG data, net sales for the first quarter were $2.22 billions, meeting analysts’ expectations ** Adjusted earnings per share for the first quarter were $1.98, higher than the expected $1.94 ** Out of 18 brokerages, 17 gave a “buy” or higher rating, 1 gave a “hold” rating; the median price target is $127.94—data compiled by LSEG ** As of the previous trading day’s close, the stock has fallen 8.37% year-to-date (To facilitate non-English speakers, Reuters has automated its reports into several other languages. As automated translations may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them as a convenience to readers. Reuters assumes no liability for any harm or loss arising from the use of automatic translation functions.)
BUZZ - Stryker shares fall as long-time CEO Lobo steps down, with COO Styles set to succeed
October 6th - Stryker (SYK.N) shares fell more than 3% in pre-market trading to $275.44. Current President and Chief Operating Officer Spencer Stiles will succeed Kevin Lobo as the CEO of the medical device manufacturer. Lobo, who has served as CEO since 2012, will become Executive Chairman starting January 1. Lobo oversaw more than 60 acquisitions, including the purchase of robotic surgery company Mako, which helped transform the orthopedic sector. Out of 29 brokerage firms, 24 rate the stock as "buy" or higher, while 5 recommend "hold"; the median target price is $380, according to data compiled by LSEG. As of the previous trading day's close, the stock was down 18.85% year-to-date. (For the convenience of non-English speakers, Reuters has automated the translation of its report into several other languages. As automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters assumes no responsibility for any damages or losses arising from the use of automated translation features.)
BUZZ - ArriVent shares fall as its lung cancer drug fails to meet goals in late-stage clinical trial
On October 6, shares of drug developer ArriVent BioPharma (AVBP.O) dropped 62.7% to $10.62 in pre-market trading. The company stated that its experimental drug firmonertinib failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation. In the higher-dose group, the median time patients lived without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; additionally, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group. In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported. ArriVent is reviewing the full results to determine the next steps for the drug's development. As of the previous trading day's close, AVBP had risen 41.5% so far this year. (For ease of use by non-English speakers, Reuters offers its reports translated automatically into several languages. Automated translations may be inaccurate or may not adequately convey the intended meaning. Reuters does not guarantee the accuracy of these translations and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses incurred from the use of the automated translation service.)
Crypto prices
More
